{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:58:13Z","timestamp":1789354693259,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.wneu.2024.123579","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:21:44Z","timestamp":1737544904000},"page":"123579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Diffuse Intrinsic Pontine Glioma and Chimeric Antigen Receptor T-Cell Therapy: An Emerging Frontier"],"prefix":"10.1016","volume":"194","author":[{"given":"Tomasz","family":"Tykocki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2024.123579_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3340\/jkns.2018.0008","article-title":"Diffuse intrinsic pontine glioma: clinical features, molecular genetics, and novel targeted therapeutics","volume":"61","author":"Mathew","year":"2018","journal-title":"J\u00a0Korean Neurosurg Soc"},{"key":"10.1016\/j.wneu.2024.123579_bib2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ejrad.2016.02.004","article-title":"Diffusion tensor imaging suggests extrapontine extension of pediatric diffuse intrinsic pontine gliomas","volume":"85","author":"Wagner","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.wneu.2024.123579_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.14791\/btrt.2023.0011","article-title":"Epigenetic and metabolic changes in diffuse intrinsic pontine glioma","volume":"11","author":"Park","year":"2023","journal-title":"Brain Tumor Res Treat"},{"key":"10.1016\/j.wneu.2024.123579_bib4","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00381-022-05482-y","article-title":"Leptomeningeal and subependymal seeding of diffuse intrinsic pontine glioma: a case report","volume":"38","author":"Parenrengi","year":"2022","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.wneu.2024.123579_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.56.6.773","article-title":"Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage","volume":"56","author":"Bailey","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2024.123579_bib6","first-page":"840","article-title":"Diffuse intrinsic pontine glioma: molecular landscape, evolving treatment strategies and emerging clinical trials","volume":"12","author":"Damodharan","year":"2022","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.wneu.2024.123579_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-020-00992-9","article-title":"Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma","volume":"8","author":"Georgescu","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.wneu.2024.123579_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","article-title":"K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas","volume":"124","author":"Khuong-Quang","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2024.123579_bib9","article-title":"Molecular alterations in pediatric brainstem gliomas","volume":"65","author":"Porkholm","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.wneu.2024.123579_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3171\/2012.3.PEDS11316","article-title":"Diffuse intrinsic pontine tumors: a study of primitive neuroectodermal tumors versus the more common diffuse intrinsic pontine gliomas","volume":"10","author":"Sufit","year":"2012","journal-title":"J\u00a0Neurosurg Pediatr"},{"key":"10.1016\/j.wneu.2024.123579_bib11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11060-011-0681-7","article-title":"Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"106","author":"Chassot","year":"2011","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.123579_bib12","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1039\/C9DT04862F","article-title":"Oxaliplatin and [Pt(R,R-DACH)(panobinostat-2H)] show nanomolar cytotoxicity towards diffuse intrinsic pontine glioma (DIPG)","volume":"49","author":"Boulet MH","year":"2020","journal-title":"Dalton Trans"},{"key":"10.1016\/j.wneu.2024.123579_bib13","series-title":"In Diffuse Intrinsic Pontine Gliomas, Non-Coding RNA Expression Is Significantly Varied Dependent on Overall Survival","author":"Castillo","year":"2021"},{"key":"10.1016\/j.wneu.2024.123579_bib14","series-title":"Non-Coding RNA Are Differentially Expressed in Diffuse Intrinsic Pontine Gliomas Based on Overall Survival","author":"Mamoor","year":"2020"},{"key":"10.1016\/j.wneu.2024.123579_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41698-017-0033-y","article-title":"Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event","volume":"1","author":"Koschmann","year":"2017","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.wneu.2024.123579_bib16","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.3390\/cancers13215280","article-title":"New developments in the pathogenesis, therapeutic targeting, and treatment of H3K27M-mutant diffuse midline glioma","volume":"13","author":"Argersinger","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.wneu.2024.123579_bib17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3k27m-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2024.123579_bib18","article-title":"HER2 chimeric antigen receptor T cell Immunotherapy is an effective treatment for diffuse intrinsic pontine glioma","volume":"5","author":"Wang","year":"2023","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.wneu.2024.123579_bib19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-Human bioactivity and safety","volume":"13","author":"Vitanza","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.wneu.2024.123579_bib20","article-title":"Intracranial cannula implantation for serial locoregional chimeric antigen receptor (CAR) T cell infusions in mice","volume":"192","author":"Harvey","year":"2023","journal-title":"J Vis Exp"},{"key":"10.1016\/j.wneu.2024.123579_bib21","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2024.123579_bib22","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.3390\/ijms22052404","article-title":"New era of immunotherapy in pediatric brain tumors: chimeric antigen receptor T-cell therapy","volume":"22","author":"Wu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.wneu.2024.123579_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A\u00a0single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.wneu.2024.123579_bib24","first-page":"5261","article-title":"Epidemiology, diagnostic strategies, and therapeutic advances in diffuse midline glioma","volume":"12","author":"Llordes","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.wneu.2024.123579_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/bioengineering5040088","article-title":"Cutting edge therapeutic insights derived from molecular biology of pediatric high-grade glioma and diffuse intrinsic pontine glioma (DIPG)","volume":"5","author":"Bailey","year":"2018","journal-title":"Bioengineering"},{"key":"10.1016\/j.wneu.2024.123579_bib26","series-title":"Craniospinal Irradiation as a Salvage Treatment for Metastatic Relapsed DIPG","author":"Perez-Somarriba","year":"2020"},{"key":"10.1016\/j.wneu.2024.123579_bib27","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/neuonc\/noab300","article-title":"Dual IGF1R\/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3k27m-mutant","volume":"24","author":"Billy","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.123579_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.wneu.2024.123579_bib29","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2024.123579_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","article-title":"B7-H3-Redirected chimeric antigen receptor T cells target glioblastoma and neurospheres","volume":"47","author":"Nehama","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.wneu.2024.123579_bib31","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.wneu.2024.123579_bib32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11060-022-04216-z","article-title":"Conventional and emerging treatments of astrocytomas and oligodendrogliomas","volume":"162","author":"Kessler","year":"2023","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.123579_bib33","article-title":"Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas","author":"Monje","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.wneu.2024.123579_bib34","article-title":"HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma","volume":"5","author":"Wang","year":"2023","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.wneu.2024.123579_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2968","article-title":"Disrupting the CD47-SIRP\u03b1 anti-phagocytic axis by a humanized anti-Cd47 antibody is an efficacious treatment for malignant pediatric brain tumors","volume":"9","author":"Gholamin","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.wneu.2024.123579_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1434464","article-title":"Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma","volume":"7","author":"Suryadevara","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.wneu.2024.123579_bib37","article-title":"Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications","volume":"10","author":"Han","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.wneu.2024.123579_bib38","series-title":"Convection-Enhanced Delivery in Children: Techniques and Applications","author":"Aquilina","year":"2022"},{"key":"10.1016\/j.wneu.2024.123579_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2024.1349612","article-title":"Current immunotherapeutic approaches to diffuse intrinsic pontine glioma","volume":"15","author":"Lin","year":"2024","journal-title":"Front Genet"},{"key":"10.1016\/j.wneu.2024.123579_bib40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","article-title":"B7-H3-Targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.wneu.2024.123579_bib41","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.27389","article-title":"EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma","volume":"10","author":"Ravanpay","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2024.123579_bib42","series-title":"Phase I Trial Evaluating Locoregionally-Delivered IL13R\u03b12-targeting CAR T Cells in High-Grade Glioma","author":"Brown","year":"2023"},{"key":"10.1016\/j.wneu.2024.123579_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.wneu.2024.123579_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor\u2013engineered T cells effectively targets HER2+ Breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2024.123579_bib45","doi-asserted-by":"crossref","first-page":"24275","DOI":"10.1073\/pnas.1903854116","article-title":"Long-term in\u00a0vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in Mice","volume":"116","author":"Mulazzani","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.wneu.2024.123579_bib46","series-title":"PD-1 Blockade Does Not Improve Efficacy of EpCAM-directed CAR T-Cells in Lung Cancer Brain Metastasis","author":"Blobner","year":"2024"},{"key":"10.1016\/j.wneu.2024.123579_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2163781","article-title":"In\u00a0vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer","volume":"12","author":"Xu","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.wneu.2024.123579_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1145706","article-title":"Anti-tumor efficacy of anti-Gd2 CAR NK-92 cells in diffuse intrinsic pontine gliomas","volume":"14","author":"Zuo","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.wneu.2024.123579_bib49","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2024.123579_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-022-06783-1","article-title":"EGFR as a potent CAR T target in triple negative breast cancer brain metastases","volume":"197","author":"Subham","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.wneu.2024.123579_bib51","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2124058","article-title":"Immunotherapy approaches for the treatment of diffuse midline gliomas","volume":"11","author":"Bernstock","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.wneu.2024.123579_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jocn.2018.06.005","article-title":"Hyaluronic acid based low viscosity hydrogel as a novel carrier for convection enhanced delivery of CAR T cells","volume":"56","author":"Atik","year":"2018","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.wneu.2024.123579_bib53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/ph17010077","article-title":"Topical delivery of tofacitinib in dermatology: the promise of a novel therapeutic class using biodegradable dendritic polyglycerol sulfates","volume":"17","author":"Zabihi","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.wneu.2024.123579_bib54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ila2.31","article-title":"Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods","volume":"2","author":"Zou","year":"2024","journal-title":"Ilabmed"},{"key":"10.1016\/j.wneu.2024.123579_bib55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1215\/15228517-2007-007","article-title":"Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions","volume":"9","author":"Sampson","year":"2007","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.123579_bib56","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ymthe.2018.02.001","article-title":"Adoptive Transfer of IL13R\u03b12-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblastoma","volume":"26","author":"Pituch","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.wneu.2024.123579_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1288383","article-title":"CAR-T treatment for cancer: prospects and challenges","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.wneu.2024.123579_bib58","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.mri.2013.07.003","article-title":"Reduced field-of-view DTI segmentation of cervical spine tissue","volume":"31","author":"Tang","year":"2013","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.wneu.2024.123579_bib59","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/biomedicines10071738","article-title":"Site-specific considerations on engineered T cells for malignant gliomas","volume":"10","author":"Elmadany","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.wneu.2024.123579_bib60","first-page":"1507","article-title":"CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges","volume":"31","author":"Narkhede","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.wneu.2024.123579_bib61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0090-3019(82)80031-1","article-title":"Brainstem hemorrhages and increased intracranial pressure: from duret to computed tomography","volume":"17","author":"Alexander","year":"1982","journal-title":"Surg Neurol"},{"key":"10.1016\/j.wneu.2024.123579_bib62","first-page":"50","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"Suppl 1","key":"10.1016\/j.wneu.2024.123579_bib63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.wneu.2024.123579_bib64","article-title":"Charting new paradigms for CAR-T cell therapy beyond current achilles heels","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.wneu.2024.123579_bib65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","article-title":"American Society for Blood and Marrow Transplantation Pharmacy special interest group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States","volume":"25","author":"Mahmoudjafari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.wneu.2024.123579_bib66","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/cpt.2986","article-title":"Best practices and considerations for clinical pharmacology and pharmacometric aspects for optimal development of CAR-T and TCR-T cell therapies: an industry perspective","volume":"114","author":"Mody","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.wneu.2024.123579_bib67","article-title":"Targeting of the targeting of the alphav beta3 integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma","volume":"10","author":"Lee","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.wneu.2024.123579_bib68","series-title":"Elucidation of CRISPR-Cas9 Application in Novel Cellular Immunotherapy","author":"Quazi","year":"2021"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875024020291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875024020291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:05:19Z","timestamp":1750226719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875024020291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":68,"alternative-id":["S1878875024020291"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2024.123579","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diffuse Intrinsic Pontine Glioma and Chimeric Antigen Receptor T-Cell Therapy: An Emerging Frontier","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2024.123579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"123579"}}